XML 60 R47.htm IDEA: XBRL DOCUMENT v3.20.2
Organization and Summary of Significant Accounting Policies - Schedule of Company's Revenue by Type (Detail) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Jun. 30, 2020
Mar. 31, 2020
Dec. 31, 2019
 [1]
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Disaggregation Of Revenue [Line Items]                      
Total revenue $ 93.2 $ 164.0 $ 195.1 $ 186.3 $ 215.4 $ 216.6 $ 216.8 $ 202.3 $ 638.6 $ 851.1 $ 743.7
Molecular Diagnostic - Hereditary Cancer Testing [Member]                      
Disaggregation Of Revenue [Line Items]                      
Total revenue                 347.4 479.7 471.4
Molecular Diagnostic - GeneSight [Member]                      
Disaggregation Of Revenue [Line Items]                      
Total revenue                 74.1 112.6 124.9
Molecular Diagnostic - Prenatal [Member]                      
Disaggregation Of Revenue [Line Items]                      
Total revenue                 76.7 104.9  
Molecular Diagnostic- Vectra [Member]                      
Disaggregation Of Revenue [Line Items]                      
Total revenue                 39.1 48.3 55.2
Molecular Diagnostic - Prolaris [Member]                      
Disaggregation Of Revenue [Line Items]                      
Total revenue                 24.7 25.5 21.5
Molecular Diagnostic - EndoPredict [Member]                      
Disaggregation Of Revenue [Line Items]                      
Total revenue                 10.5 10.4 8.8
Molecular Diagnostic - Other [Member]                      
Disaggregation Of Revenue [Line Items]                      
Total revenue                 14.4 8.0 8.6
Molecular Diagnostic Testing [Member]                      
Disaggregation Of Revenue [Line Items]                      
Total revenue 83.3 150.5 181.1 172.0 196.9 200.5 203.0 189.0 586.9 789.4 690.4
Pharmaceutical and Clinical Services [Member]                      
Disaggregation Of Revenue [Line Items]                      
Total revenue $ 9.9 $ 13.5 $ 14.0 $ 14.3 $ 18.5 $ 16.1 $ 13.8 $ 13.3 $ 51.7 $ 61.7 $ 53.3
[1] An immaterial prior period goodwill impairment charge of $1.3 million was previously classified as part of selling, general and administrative expense in the condensed consolidated statements of operations was reclassified to conform to the current period presentation and is included as part of the goodwill and intangible asset impairment charges financial statement line item in the current period.